Switched to a daily pill after injections, patients kept three-quarters of the loss

One of the persistent questions around GLP-1 drugs is what happens after someone reaches their weight-loss goal on an injectable drug: continue injections indefinitely, stop and risk regain, or switch to something else. The ATTAIN-MAINTAIN trial, published this week in Nature Medicine, tests a third option — switching to orforglipron, the once-daily oral GLP-1 drug — as a maintenance strategy [s1].

The design

This double-blind, placebo-controlled phase 3b trial drew its participants from the earlier SURMOUNT-5 study, which had compared tirzepatide against semaglutide [s1]. Participants who had reached a body-weight plateau on either drug were randomized into two separate cohorts: cohort 1, previously on tirzepatide (n=205), and cohort 2, previously on semaglutide (n=171) [s1]. Within each cohort, participants were randomized to switch to once-daily oral orforglipron or to placebo, and followed for 52 weeks [s1]. The trial measured how much of participants' prior weight loss was maintained, using a model-based estimate (MBE) under the treatment-regimen estimand — an analysis that accounts for people who stopped treatment or deviated from the protocol, reflecting real-world use more closely than an efficacy-only analysis would [s1].

What it found

In cohort 1 (previously on tirzepatide), participants who switched to orforglipron maintained an estimated 74.7% of their prior body weight reduction at week 52, compared with 49.2% maintained on placebo — a treatment difference of 25.5 percentage points (95% CI 14.5–36.5, p < 0.001) [s1]. In cohort 2 (previously on semaglutide), the gap was even larger: orforglipron maintained 79.3% of prior weight loss compared with 37.6% on placebo, a treatment difference of 41.7 percentage points (95% CI 24.4–59.0, p < 0.001) [s1]. All prespecified key secondary endpoints were also met [s1]. The most common adverse events were gastrointestinal and mostly mild to moderate in severity [s1].

Reading the two cohorts side by side

The placebo groups in both cohorts illustrate the regain pattern already well documented for GLP-1 drugs: stopping treatment led people to keep less than half of their prior weight loss at one year (49.2% and 37.6% maintained, respectively) [s1] — consistent with prior research on post-discontinuation regain. What ATTAIN-MAINTAIN adds is a specific comparison: switching to a different, oral drug in the same class preserved substantially more of that loss than stopping altogether, in both the tirzepatide-prior and semaglutide-prior groups.

The larger treatment effect in cohort 2 (semaglutide-prior, 41.7-point gap) versus cohort 1 (tirzepatide-prior, 25.5-point gap) is a notable asymmetry the trial doesn't fully explain — it may reflect differences in how much weight each group lost initially, differences in placebo-arm regain rates between the two prior-drug populations, or other unmeasured factors, and the paper's summary doesn't isolate the cause.

What this doesn't establish

This trial has a real structural limitation the authors state directly: there was no comparator arm involving continued use of the original injectable drug (tirzepatide or semaglutide) [s1] — meaning the trial shows orforglipron beats placebo as a maintenance strategy, but doesn't show how switching to orforglipron compares against simply staying on the original injectable. That's the more clinically relevant question for a patient actually weighing options, and it remains unanswered here. The trial also ran one year, so durability beyond that window, and what happens if orforglipron itself is eventually stopped, are both unaddressed [s1].

Why this matters

Orforglipron's core appeal — a pill rather than an injection — has already been established in trials against placebo and against other drugs for initial weight loss. This trial extends that appeal to the maintenance phase specifically, positioning oral orforglipron as what the authors call "a globally scalable option for minimizing weight changes after injectable therapy" [s1] — language pointing toward global access and convenience advantages of an oral drug, particularly relevant in settings where injectable drug supply, cost, or cold-chain logistics are more limiting factors than they are in wealthier markets.

What to watch

A head-to-head trial comparing orforglipron maintenance against continued injectable therapy, and longer-term data beyond the 52-week window tested here. Orforglipron is being reviewed by regulators; this article describes investigational drug trial results and is not medical advice.

Sources

1. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — Nature Medicine, 13 May 2026